The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Texas MPN Workshop 2022 | FDA approval of pemigatinib for R/R myeloid/lymphoid neoplasms: a major advance in the field
In this video, Prithviraj Bose, MBBS, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the recent approval of pemigatinib for the treatment of patients with relapsed/refractory (R/R) myeloid/lymphoid neoplasms with FGFR1 rearrangement. Dr Bose highlights the challenges of treating these patients and further explains the impact of this approval in the field. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
